DUBLIN – A flurry of deals in late September added a burst of energy to what was otherwise a pretty sleepy third quarter for European biotech firms engaged in drug development. The last week of the month – and of the quarter – was a particularly busy one. European firms raised $472 million during that time, more than half of the total third-quarter raise, which came to $837 million.